S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
about
New advances in targeted gastric cancer treatmentNovel targets in the treatment of advanced gastric cancer: a perspective reviewCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationEfficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysisEfficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system reviewTargeted therapy in gastroesophageal cancers: past, present and future.Effect of tumor-associated macrophages on gastric cancer stem cell in omental milky spots and lymph node micrometastasisNimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.Advanced gastric adenocarcinoma: optimizing therapy options.Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer.The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis.Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis.Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience.Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma.Additional induction chemotherapy to concurrent chemotherapy and intensity-modulated radiotherapy with or without nimotuzumab in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: a propensity score matched analysis.Current therapeutic landscape for advanced gastroesophageal cancers.Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in vitro.New therapeutic options opened by the molecular classification of gastric cancer.
P2860
Q26738548-7A38B528-E234-40E6-820B-F9128CA36431Q26765208-EC231D65-DE80-4EA8-A648-D8033D870D07Q26765941-E474ABA4-4BF8-4EE8-8AF2-9901F216E204Q33441654-1122FD55-AD4C-42F6-A508-3024AB42C315Q36134904-C002EA23-BA35-480C-B47F-EF45342C2FD2Q36294579-EC29AFC8-72A2-4B07-A586-32574853C9C1Q36464260-649C8ED9-834C-43E0-A341-4E9D0743E94DQ37269328-3E266079-EA90-49F1-93AE-25B08722E6ACQ37618803-67A00905-114F-4506-8005-F015CD0C0B13Q39091817-13F0958E-3DA4-41A2-93F8-1D55E61F83E2Q41484436-3EDD0E7E-37D8-4D25-93CE-EEA8CD93B4C4Q42265610-5C1D08D0-CF6E-444E-9406-B8E99511D392Q45357051-C9D21952-8353-4873-91CD-83A00B6F6281Q47120612-51E1B653-E7BB-4183-AEEE-B6113EDBF443Q47301004-F3A2462D-7C10-4FCF-8332-FBF65466994AQ47402625-DB4A0FCC-C297-47A9-B4E5-8DF2603579E9Q50095911-6C2E39A5-2F43-4BB1-9A0F-F1F7BE07AECEQ50311224-192B2F8E-B51E-4210-9623-664CE42D1658Q52581752-F133E245-E157-4B61-9F42-259631A45810Q52725862-78F23FCF-3A9E-4B42-A024-BEBAF4D87E86Q55527185-A16A3DA4-5C22-4054-97D8-18D97E934D96
P2860
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@ast
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@en
type
label
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@ast
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@en
prefLabel
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@ast
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@en
P2093
P2860
P1433
P1476
S-1 and Cisplatin With or With ...... ized, Open-Label Phase 2 Trial
@en
P2093
Jinwan Wang
Jiuda Zhao
SuSheng Shi
Xinhua Yuan
Yihebali Chi
Yongkun Sun
P2860
P356
10.1097/MD.0000000000000958
P407
P577
2015-06-01T00:00:00Z